An assistant professor and OB/GYN at a northeast academic medical center is specialized in reproductive endocrinology and infertility. This stakeholder discusses adoption of precision medicine in the fertility and IVF space, such as endometrial receptivity analysis.They consider unmet needs greatest for research, demonstrated clinical utility/validity, and treatments. They rate unmet needs highest in endometriosis, PCOS, pregnancy complications, perinatal conditions, fertility, and contraceptives and the activity for precision medicine in the next 1-2 years highest in endometriosis, pregnancy complications, and artificial conception. This stakeholder believes there is significant unmet need in assessing lifetime fertility and would like to see “precision timing” tools to screen/prognosticate infertility, ovarian failure, and rate of follicle loss. They are excited by activity by DotLab, Oviva Therapeutics, and Celmatix. In the future, this stakeholder expects growth to be driven by areas related to fertility due to the potential for out-of-pocket payments and continued investment from the private sector rather than government/NIH. They believe artificial intelligence (AI) and RNA/microRNA will be key enabling tech modalities.

Campaign Details

Precision Medicine Opportunities in Women’s Health Ad Board

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.